Frankfurt - Delayed Quote EUR

Hofseth BioCare ASA (HBQ.F)

0.1820

+0.0060

+(3.41%)

At close: May 16 at 9:39:12 PM GMT+2

Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT

HBC recorded total operating revenues of NOK 60.9 million in the first quarter of 2025, compared to NOK 52.4 million in the same period last year. Net operating revenues were NOK 60.7 million, reflecting a 15% increase from Q1 2024 (NOK 52.1 million), driven by continued growth in higher-margin human and pet health segments, despite early-quarter production constraints and ongoing pressure in the commodity oil market. Cost of goods sold (CoGS) amounted to NOK 37.5 million, up from NOK 27.3 milli

GlobeNewswire yesterday

HOFBF
Hofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SPECTRUM OMEGAS IN THE US

Nestlé-owned Garden of Life has launched OmeGo® Full Spectrum Omegas on Amazon in the US. Branded as “Norwegian Salmon Oil”, it retains the complete balance and nutritional profile of fresh Atlantic salmon in a softgel format. Joining Garden of Life’s portfolio of health supplements available online, Norwegian Salmon Oil containing OmeGo® is gently liberated from fresh, sashimi-grade salmon and provides whole-fish health benefits from its full spectrum of omegas. It differentiates from a competi

GlobeNewswire 12 days ago

HOFBF
Hofseth Biocare ASA: SUCCESSFUL PLACEMENT OF NEW CHF-DENOMINATED UNSECURED BONDS

Reference is made to the stock exchange notice published by Hofseth BioCare ASA (the "Company") on 10 March 2025 regarding a contemplated bond issuance. The Company is pleased to announce that it has now successfully placed CHF-denominated unsecured bonds for a total amount of approximately CHF 3.5 million (the "Bonds"). The Bonds were subscribed for by investors in Switzerland and Liechtenstein. Settlement of the Bonds issue is expected to occur simultaneously as the issue date, which is expect

GlobeNewswire 12 days ago

HOFBF
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2025

The Annual General Meeting of Hofseth BioCare ASA for 2025 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 23 May 2025 at 13:00 CET. The notice of the Annual General Meeting is attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: +47 93632966 E-mail: investor@hofsethbiocare.no About Hofseth BioCare ASA: Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainability,

GlobeNewswire 15 days ago

HOFBF
Hofseth Biocare ASA: HBC ANNUAL REPORT 2024

The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2024, and HBC has today published the Annual Report and Sustainability Report for 2024. Please find the Annual Report and ESG Report attached. For further information, please contact:Jon Olav Ødegård, CEO of Hofseth BioCare ASAPhone: +47 93632966E-mail: joo@hofsethbiocare.no About Hofseth BioCare ASA:Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainab

GlobeNewswire last month

HOFBF
Hofseth Biocare ASA: CONTEMPLATING UNSECURED BOND ISSUANCE

Hofseth BioCare ASA has retained Novum Asset Management AG to investigate the potential issuance of CHF-denominated unsecured bonds with an expected volume of up to CHF 8 million, towards investors in Switzerland and Liechtenstein. Further, the Company may contact investors in Norway directly. The Company targets a tenor of three years for the Bonds. Further information about any issuance of Bonds, and the terms and conditions of such bonds, will be given in due course. For further information,

GlobeNewswire 2 months ago

HOFBF
Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP

HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through a EUR 5m loan. The partnership ideally complements both HBC and Symrise’s current portfolio with science-led, clinically proven marine ingredients for Consumer Health. HBC have also signed an exclusive distribution agreement for OmeGo®, ProGo® and NT-II™ into the Consumer Health and Functional Food c

GlobeNewswire 2 months ago

HOFBF
Hofseth Biocare ASA: FOURTH QUARTER & FULL YEAR 2024 FINANCIAL REPORT

HBC achieved full-year sales revenue of NOK 256.8 million, a 35% increase from 2023, with strong momentum in higher-margin B2B human nutrition. The shift towards premium products, particularly CalGo® and OmeGo®, contributed to the revenue boost, while gross margins improved across all segments. The company’s restructuring efforts in Q4 led to improved scalability, with cost optimization initiatives streamlining operations. Organization re-structuring during the fourth quarter, resulted in one-ti

GlobeNewswire 2 months ago

HOFBF
Hofseth Biocare ASA: Commences the project for a second hydrolysis plant in Norway to triple capacity

Hofseth BioCare ASA ("HBC" or the "Company", and together with its consolidated subsidiaries, the "Group") is pleased to announce a Board resolution to start a project to build a second hydrolysis plant in Berkåk, Norway through HBC Berkåk AS ("HBC Berkåk"), a wholly owned subsidiary of the Company. HBC Berkåk will be engaged within the manufacturing, marketing and sale of clinically proven, human grade, sustainable marine proteins, collagens, and oils from Norwegian Atlantic salmon harvested fr

GlobeNewswire 5 months ago

HOFBF
Hofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT

HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating loss (EBITDA) for the quarter was NOK -21.0m (-16.2m) and NOK -39.2m (-26.3m) for the first nine months. Operating result (EBIT) amounted to NOK -30.5m (-25.2m) in the third quarter 2024. Cash and cash equivalents decreased by NOK 1.9m during the quarter, leaving a total holding at NOK 23.4m at the end of September, compared to NOK 25.3m at the end of the sec

GlobeNewswire 6 months ago

HOFBF
Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT

Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral formulation in combination with standard of care hormonal-targeting therapy. Oral FT-002a significantly augmented the anti-tumour activity of enzalutamide (Xtandi®) the market-leading androgen receptor inhibitor, in models of indolent and aggressive prostate cancers. Prostate cancer remains the mos

GlobeNewswire 7 months ago

HOFBF
Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT

HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half year. Adjusted for the sale of assets in the second quarter, sales revenues were NOK 72.2m (50.7m) for the quarter, representing an increase compared to the same quarter in 2023 of 42 percent. Cash and cash equivalents increased by NOK 3.1m during the quarter, leaving total holding at NOK 25.3m at the end of June, compared to NOK 22.4m at the end of March. Including credit facilities,

GlobeNewswire 8 months ago

HOFBF
Hofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY

Ålesund, Norway, 14 August, 2024 - Hofseth BioCare (HBC), a leader in science-led marine nutrition, proudly announces compelling new findings from a recent study on the benefits of its enzymatically liberated salmon oil, OmeGo®, for COVID-19 recovery. Published in the International Journal of Molecular Sciences, this pioneering research demonstrates that OmeGo® has the potential to improve immune responses and reduce inflammation in individuals with mild to moderate COVID-19 infection, caused by

GlobeNewswire 8 months ago

HOFBF
Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.

Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate MA-022a to its majority-owned subsidiary HBC Immunology Inc. ("HBCI"). The patent underlying the project has been valued by KWC AS at $4.5m (based on relief-from royalty method) and HBC will therefore receive 956,813 common shares in HBCI for the transfer of the patent to HBCI. HBC has booked approx

GlobeNewswire 10 months ago

HOFBF
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an additional distributor in China. Shanghai-based Lithy has entered into an agreement with HBC to distribute its science-led marine nutrition ingredients, ProGo® bioactive peptides, OmeGo® full spectrum omegas and CalGo® natural, undenatured type II collagen, to supplement manufacturers across the country. Lithy, which was established in 2002, has three subsidiaries that su

GlobeNewswire 10 months ago

HOFBF

Performance Overview

Return	HBQ.F	OBX Total Return Index (OBX.OL)
YTD	+11.31%	+11.38%
1-Year	+6.12%	+11.62%
3-Year	-44.85%	+33.07%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hofseth BioCare ASA (HBQ.F)

Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT

Hofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SPECTRUM OMEGAS IN THE US

Hofseth Biocare ASA: SUCCESSFUL PLACEMENT OF NEW CHF-DENOMINATED UNSECURED BONDS

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2025

Hofseth Biocare ASA: HBC ANNUAL REPORT 2024

Hofseth Biocare ASA: CONTEMPLATING UNSECURED BOND ISSUANCE

Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP

Hofseth Biocare ASA: FOURTH QUARTER & FULL YEAR 2024 FINANCIAL REPORT

Hofseth Biocare ASA: Commences the project for a second hydrolysis plant in Norway to triple capacity

Hofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT

Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT

Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT

Hofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY

Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

Performance Overview